---
figid: PMC3811159__nihms512981f3
figtitle: Feedback signaling following PI3K, AKT, or dual mTORC1/2 inhibition
organisms:
- Homo sapiens
- Mus musculus
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3811159
filename: nihms512981f3.jpg
figlink: /pmc/articles/PMC3811159/figure/F3/
number: F3
caption: Feedback signaling following PI3K, AKT, or dual mTORC1/2 inhibition. (A)
  The baseline status of the PI3K signaling cascade, indicating negative feedback
  to RTKs such as HER3 and IGF1R, via inactivation of the FOXO transcription factors
  by AKT. (B) PI3K, AKT, or dual mTORC1/2 inhibitor inactivate AKT, releasing the
  inhibition of FOXO transcription factors, leading to expression and activation of
  HER3, IGF1R, and other RTKs, leading to activation of PI3K and AKT activation, and
  potentially other pathways (i.e. RAS-RAF-MEK-ERK). This effect is delayed in vitro
  by 24–72 hours or more, and represents a reequilibration of the pathway over time.
  (C) The addition RTK inhibitors can block the compensatory signaling and induce
  synergy with PI3K, AKT, and/or dual mTORC1/2 inhibitors.
papertitle: Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma.
reftext: Lawrence N. Kwong, et al. Clin Cancer Res. ;19(19):10.1158/1078-0432.CCR-13-0142.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.936502
figid_alias: PMC3811159__F3
figtype: Figure
redirect_from: /figures/PMC3811159__F3
ndex: 388b57a8-deee-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3811159__nihms512981f3.html
  '@type': Dataset
  description: Feedback signaling following PI3K, AKT, or dual mTORC1/2 inhibition.
    (A) The baseline status of the PI3K signaling cascade, indicating negative feedback
    to RTKs such as HER3 and IGF1R, via inactivation of the FOXO transcription factors
    by AKT. (B) PI3K, AKT, or dual mTORC1/2 inhibitor inactivate AKT, releasing the
    inhibition of FOXO transcription factors, leading to expression and activation
    of HER3, IGF1R, and other RTKs, leading to activation of PI3K and AKT activation,
    and potentially other pathways (i.e. RAS-RAF-MEK-ERK). This effect is delayed
    in vitro by 24–72 hours or more, and represents a reequilibration of the pathway
    over time. (C) The addition RTK inhibitors can block the compensatory signaling
    and induce synergy with PI3K, AKT, and/or dual mTORC1/2 inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGF1R
  - EGFR
  - ERBB2
  - ERBB3
  - ERBB4
  - IRS1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - AKT1
  - AKT2
  - AKT3
  - RPTOR
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Crtc
  - AZD8055
  - MK-2206
---
